Document Detail


1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
MedLine Citation:
PMID:  20406950     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The tumor suppressor p53 is often referred to as "the guardian of the genome" because of its central role in the cellular response to oncogenic stress and prevention of tumor development. Mutations of p53 in acute myeloid leukemia (AML) are rare but resistance to chemotherapy has been reported because of the deregulation of the p53 signaling and differentiation pathways. It is known that the interaction of the vitamin D metabolite 1,25-dihydroxyvitamin D(3) (1,25D) with its functional vitamin D receptor leads to differentiation, G(1) arrest, and increased cell survival in p53-null AML cells. However, there are no reports on the effect of 1,25D in leukemia cells expressing wild-type p53. Here, we examine vitamin D signaling in AML cells MOLM-13 and OCI-AML3 expressing wild-type p53 in the presence and absence of the MDM2 antagonist nutlin-3. We find that 1,25D alone induces monocytic differentiation in these cell lines similar to that seen in p53-null AML cells, suggesting that the presence of wild-type p53 is compatible with activation of vitamin D signaling. Combination of nutlin-3a with 1,25D accelerated programmed cell death, likely because of enhanced nutlin-induced upregulation of the proapoptotic PIG-6 protein and downregulation of antiapoptotic BCL-2, MDMX, human kinase suppressor of Ras 2, and phosphorylated extracellular signal-regulated kinase 2.
Authors:
Thelma Thompson; Michael Andreeff; George P Studzinski; Lyubomir T Vassilev
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-04-20
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  9     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-11     Completed Date:  2010-08-20     Revised Date:  2014-09-11    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1158-68     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Apoptosis / drug effects*
Calcitriol / administration & dosage,  pharmacology*
Cell Differentiation / drug effects
Cell Line, Tumor
Drug Evaluation, Preclinical
Drug Synergism
Gene Expression Regulation, Leukemic / drug effects
Genes, p53*
HL-60 Cells
Humans
Imidazoles / administration & dosage*,  pharmacology
Leukemia, Myeloid, Acute / drug therapy*,  genetics,  pathology
Monocytes / drug effects,  physiology
Piperazines / administration & dosage*,  pharmacology
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
Up-Regulation / drug effects
Grant Support
ID/Acronym/Agency:
R01 CA044722/CA/NCI NIH HHS; R01 CA044722-20/CA/NCI NIH HHS; R01-CA-44722-20/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Imidazoles; 0/Piperazines; 0/nutlin 3; EC 6.3.2.19/MDM2 protein, human; EC 6.3.2.19/Proto-Oncogene Proteins c-mdm2; FXC9231JVH/Calcitriol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation a...
Next Document:  Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinas...